The use of somatropin in women with somatotropin deficiency decreases visceral fat and improves cardiovascular (CV) risk markers

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1648, 2008-01, pp. : 20-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Somatropin reduces MMP, VEGF levels in somatotropin deficiency

By  

Inpharma, Vol. 1, Iss. 1440, 2004-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Pioglitazone improves CV risk markers in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1495, 2005-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Guidance on somatropin use in GH deficiency issued by UK NICE

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 365, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Guidance on somatropin use in GH deficiency issued by UK NICE

By  

Inpharma, Vol. 1, Iss. 1340, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Somatropin increases cancer risk

By  

Inpharma, Vol. 1, Iss. 1349, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite